• Mantle Cell Lymphoma 5000612 global 1 0.5 0.5 Commentary 0 1
  Relapsed/Refractory Mantle Cell Lymphoma: Where Do Novel BTK Inhibitors Fit for Our Patients?
  Hematology-Oncology2023-03-29 20:00:00
  Have you heard about the newest noncovalent Bruton tyrosine kinase (BTK) inhibitor that has been added to the selection of BTK inhibitors used to treat relapsed/refractory (R/R) mantle cell lymphoma (MCL)?
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• 0 global 1 0.25 9 0.25 2 0.25 3 0.25 8 0.25 0.25 Clinical Case 0 1
  Caregivers: Centering Their Role in Managing Patients With Hematologic Malignancies
  Hematology-Oncology2023-03-29 20:00:00
  How much attention do you pay to the role of caregivers?
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save
• Social Determinants of Health 6010999 global 1 0.25 9 0.25 2 0.25 0.25 Roundtable 0 1
  Continuing the Conversation: Elevating Equity in Caring for Patients With Hematologic Malignancies
  Hematology-Oncology2023-03-28 20:00:00
  How confident are you at recognizing and addressing inequities in the care of patients with hematologic malignancies?
  
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save
• Breast Cancer 840 global 1 0.75 9 0.75 2 0.75 0.75 Roundtable 0 1
  Conceptualizing Guidelines to Manage Patients With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
  Hematology-Oncology2023-03-28 20:00:00
  What do the guidelines say about treating patients with early breast cancer at high risk for recurrence?
  
  0.75ABIM MOC 0.75CME/CE 45MIN

  
  Save
• Myelofibrosis 5003320 global 1 0.25 9 0.25 0.25 Roundtable 0 1
  Advances in Myelofibrosis: Updates on Emerging Treatments and Future Directions
  Hematology-Oncology2023-03-27 20:00:00
  Did you know new treatments in development are being developed for myelofibrosis with the goal of changing the disease course?
  
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save
• Ovarian Cancer 839 global 1 1.0 9 1.0 1.0 Clinical Case 0 1
  Ovarian Cancer Virtual Patient Case Simulation: How Do You Incorporate Maintenance Therapy?
  Hematology-Oncology2023-03-26 20:00:00
  Integrating maintenance therapy into treatment for patients with ovarian cancer
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• Mantle Cell Lymphoma 5000612 global 1 0.5 0.5 Commentary 0 1
  Relapsed/Refractory Mantle Cell Lymphoma: Where Do Novel BTK Inhibitors Fit for Our Patients?
  Hematology-Oncology2023-03-29 20:00:00
  Have you heard about the newest noncovalent Bruton tyrosine kinase (BTK) inhibitor that has been added to the selection of BTK inhibitors used to treat relapsed/refractory (R/R) mantle cell lymphoma (MCL)?
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• 0 global 1 0.25 9 0.25 2 0.25 3 0.25 8 0.25 0.25 Clinical Case 0 1
  Caregivers: Centering Their Role in Managing Patients With Hematologic Malignancies
  Hematology-Oncology2023-03-29 20:00:00
  How much attention do you pay to the role of caregivers?
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save
• Social Determinants of Health 6010999 global 1 0.25 9 0.25 2 0.25 0.25 Roundtable 0 1
  Continuing the Conversation: Elevating Equity in Caring for Patients With Hematologic Malignancies
  Hematology-Oncology2023-03-28 20:00:00
  How confident are you at recognizing and addressing inequities in the care of patients with hematologic malignancies?
  
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save
• Breast Cancer 840 global 1 0.75 9 0.75 2 0.75 0.75 Roundtable 0 1
  Conceptualizing Guidelines to Manage Patients With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
  Hematology-Oncology2023-03-28 20:00:00
  What do the guidelines say about treating patients with early breast cancer at high risk for recurrence?
  
  0.75ABIM MOC 0.75CME/CE 45MIN

  
  Save
• Myelofibrosis 5003320 global 1 0.25 9 0.25 0.25 Roundtable 0 1
  Advances in Myelofibrosis: Updates on Emerging Treatments and Future Directions
  Hematology-Oncology2023-03-27 20:00:00
  Did you know new treatments in development are being developed for myelofibrosis with the goal of changing the disease course?
  
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save
• Ovarian Cancer 839 global 1 1.0 9 1.0 1.0 Clinical Case 0 1
  Ovarian Cancer Virtual Patient Case Simulation: How Do You Incorporate Maintenance Therapy?
  Hematology-Oncology2023-03-26 20:00:00
  Integrating maintenance therapy into treatment for patients with ovarian cancer
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• Acute Leukemia 5005273 global 1 0.75 9 0.75 0.75 Roundtable 0 1
  Building New Bridges to Transplant: A Focus on Emerging Bridging Strategies in Acute Myeloid Leukemia
  Hematology-Oncology2023-03-26 20:00:00
  Hear updates from the winter meetings on novel approaches for getting older patients with acute myeloid leukemia (AML) to transplant.
  
  0.75ABIM MOC 0.75CME/CE 45MIN

  
  Save
• Breast Cancer 840 global 1 0.5 9 0.5 0.5 Roundtable 0 1
  Management of HR-Positive/HER2-Negative Early Breast Cancer: Taking Direction From the Updated Guidelines
  Hematology-Oncology2023-03-26 20:00:00
  Which of the guidelines for use of CDK 4/6 inhibitors do you use to guide treatment for patients with HR-positive/HER2-negative early breast cancer?
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Multiple Myeloma 1166 global 1 0.25 9 0.25 0.25 Roundtable 0 1
  Practical Management of Early Relapses in the Myeloma Clinic
  Hematology-Oncology2023-03-26 20:00:00
  What is the optimal approach to treatment for first and second relapse? Dr Lonial provides practical guidance.
  
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save
• Lung Cancer 5000186 global 1 0.25 9 0.25 0.25 Roundtable 0 1
  Quickfire: NTRK Updates Relevant for Your Practice
  Hematology-Oncology2023-03-26 20:00:00
  Do you know how to manage patients with solid tumors and NTRK fusions?
  
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save
• Non-Hodgkin Lymphoma (NHL) 1544 global 1 0.75 9 0.75 0.75 Roundtable 0 1
  Let's Talk Specifics! B-Cell Malignancies and the Emerging Role of Bispecific Antibodies
  Hematology-Oncology2023-03-26 20:00:00
  Looking for updates on the latest in bispecific antibodies in B-cell non-Hodgkin lymphoma (NHL)? Join for expert analysis to incorporate these novel agents into practice.
  
  0.75ABIM MOC 0.75CME/CE 45MIN

  
  Save
• Small Cell Lung Cancer 275 global 1 0.5 9 0.5 0.5 Roundtable 0 1
  The Link Between Neurology and Oncology: LEMS and the Risk of SCLC
  Neurology & Neurosurgery2023-03-23 20:00:00
  When an autoimmune neuromuscular disease signals the presence of small cell carcinoma.
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Advanced and Metastatic Breast Cancer 846 global 1 0.25 9 0.25 0.25 Commentary 0 1
  A Primer on Oral Selective Estrogen Receptor Degraders in Metastatic Hormone Receptor-Positive Breast Cancer
  Hematology-Oncology2023-03-22 20:00:00
  Aromatase inhibitors (AIs), selective estrogen receptor modulators (SERMs), and selective estrogen receptor degraders (SERDs). How do they work and when should they be added to the treatment of metastatic hormone receptor (HR)-positive breast cancer?
  
  0.25ABIM MOC 0.25CME/CE 15MIN

  
  Save
• Breast Cancer 840 global 1 1.0 9 1.0 1.0 Clinical Case 0 1
  Adjuvant Therapy in Hormone Receptor Positive/HER2-Negative Early Breast Cancer: Case Simulations
  Hematology-Oncology2023-03-20 20:00:00
  Do you know the best approaches for identifying and managing high-risk, hormone receptor positive early breast cancer?
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• 0 global 1 1.0 9 1.0 1.0 Clinical Case 0 1
  Investigating Anemia and the Possibility of Pyruvate Kinase Deficiency: What Is' Your Next Step?
  Hematology-Oncology2023-03-20 20:00:00
  Did you know that pyruvate kinase deficiency (PKD) is diagnosed using a combination of PK enzyme activity and PKLR molecular profiling?
  
  1.0ABIM MOC 1.0CME/CE 60MIN

  
  Save
• Chronic Lymphocytic Leukemia 1551 global 1 0.75 9 0.75 0.75 Commentary 0 1
  BTK Inhibitors for CLL and MCL: What the Latest Data Mean for Our Patients
  Hematology-Oncology2023-03-20 20:00:00
  Did you know noncovalent BTK inhibitor therapy is now an option for patients with pretreated MCL who fail a prior covalent BTK inhibitor therapy?
  
  0.75ABIM MOC 0.75CME/CE 45MIN

  
  Save
• Chronic Myelogenous Leukemia 1552 global 1 0.5 9 0.5 0.5 Roundtable 0 1
  Tyrosine Kinase Inhibitors: Optimizing Treatment Options for Patients With Chronic Myeloid Leukemia
  Hematology-Oncology2023-03-19 20:00:00
  How do you choose a tyrosine kinase inhibitor (TKI) for your patients with chronic myeloid leukemia (CML)? Join to hear an expert discussion on considerations and clinical data.
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save
• Colorectal Cancer 3032296 global 1 0.5 9 0.5 0.5 Roundtable 0 1
  Understanding the HER2-Positive Story and Revolutionizing the Future in Colorectal Cancer
  Hematology-Oncology2023-03-19 20:00:00
  Did you know that patients with left-sided colorectal cancer (CRC) tend to have greater overexpression of human epidermal growth factor receptor-2 (HER2) than those with right-sided disease?
  
  0.5ABIM MOC 0.5CME/CE 30MIN

  
  Save

Education For Your Patient

• Click here for access to online educational resources to share with your patients and their care partners

Policies and Requirements

• CME Policies
• State CME Requirements